Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Sponsor:Pfizer
Enrolling:Male and Female Patients
Age Range:Between 2 and 21 years old
IRB Number:AAAS2961
U.S. Government ID:NCT03709680
Contact: Rebecca Zylber, NP: 212-305-7212 / rjv2107@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to find the best dose of Palbociclib that can be given safely with chemotherapy in children with solid tumor which has come back or has not responded to the standard therapy. Palbociclib works by targeting proteins that are necessary for cell growth. Palbociclib will be given by mouth on Days 1-14 of a 21-day cycle. It will be given in combination with chemotherapy drugs Irinotecan and Temozolomide.

Do You Qualify?
Does your child have a recurrent or refractory solid tumor?YesNo
Is your child between 2 and 21 years old?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Rebecca Zylber, NP
Email: rjv2107@cumc.columbia.edu
Phone: 212-305-7212